OncoMatch/Clinical Trials/NCT06545630

Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases

Is NCT06545630 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Tumor antigen-sensitized DC vaccine for carcinoma.

Phase 1RecruitingWest China HospitalNCT06545630Data as of May 2026

Treatment: Tumor antigen-sensitized DC vaccine — The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Required: Stage IV

Metastatic disease required

Performance status

KARNOFSKY 0–1

Prior therapy

Must have received: surgery — resection of both primary and metastatic tumors

resection of both primary and metastatic tumors and had NED status after surgery

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify